Prior Stephen David's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Jan 7, 2026
- Accession no.
- 0001193125-26-006770
- Filed
- Jan 7, 2026
- Trade date
- Jan 5-6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $6.49K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Prior Stephen DavidCIK 0002042268 | Officer (Chief Strategy Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Common Stock | SSaleDisposed | −3,604 | $1.00 | −$3,604 | 61,944 | Direct | |
| Jan 6, 2026 | Common Stock | SSaleDisposed | −2,858 | $1.01 | −$2,886.58 | 59,086 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.